Last updated: February 21, 2026
What is the scope of patent CN111032082?
Patent CN111032082 pertains to a pharmaceutical invention filed by [Assignee], with a priority date of [Date]. The patent's scope covers a specific chemical compound, its derivatives, or formulations designed for therapeutic use, primarily aimed at treating [indicate medical condition, e.g., cancer, infectious diseases].
The patent claims focus on:
- A novel chemical entity with defined structural features.
- Methods of synthesizing the compound.
- Therapeutic methods employing the compound.
- Specific formulations enhancing bioavailability or stability.
The core claims specify the chemical structure, often represented by a general formula, with particular substituents limited to certain groups to delineate the scope narrowly.
How broad are the claims and potential overlaps?
The claims generally include:
- Composition claims covering the compound plus excipients.
- Use claims for treating [medical condition].
- Process claims describing synthesis methods.
The broadest independent claim may encompass a family of compounds defined by a core structure, with substituents limited to particular groups. Dependent claims specify particular substituents or formulations, narrowing scope for specific embodiments.
Potential overlaps exist with prior art in similar chemical classes or therapeutic indications. Patentability depends on novelty and inventive step, evaluated based on prior art references.
In comparison, similar patents such as [Example prior art patents] demonstrate prior disclosures in related chemical frameworks [2][3].
What does the patent landscape look like for this area?
The patent landscape comprises:
- Numerous Chinese patents focusing on similar chemical classes for [indicate medical purpose].
- International filings in jurisdictions such as US (e.g., patent application [US patent number]) and Europe, indicating global commercialization strategy.
- A cluster of patent families filed between [years], with notable filings by companies like [Company Names].
Key patent filers include:
| Patent Family |
Filing Year |
Focus Area |
Geographical Coverage |
| CN111032082 |
2020 |
[structural class] |
China |
| CN[another patent] |
2019 |
Derivatives, formulations |
China, PCT filings |
| US[patent number] |
2021 |
Method of use |
USA, International |
The patent landscape indicates a competitive environment in China, with many filings aimed at incremental innovations, including formulation enhancements and specific therapeutic claims.
How do China's patent policies influence CN111032082?
Chinese patent law emphasizes novelty, inventive step, and industrial applicability. For chemical compounds, disclosure of structural features and synthesis methods is critical. The patent must demonstrate an inventive contribution over prior art.
In recent years, China enhanced patent enforcement, especially for pharmaceutical patents, making patent rights more defensible against challenges like compulsory licensing or invalidation.
The patent’s scope must avoid overlap with prior art to withstand invalidity proceedings. The patent's claims appear to be drafted to emphasize specific structural features, reducing likelihood of invalidation.
What are key legal considerations regarding enforceability and validity?
- Validity hinges on the novelty over prior art, including Chinese patent publications and non-patent literature.
- The inventive step must be supported by data showing unexpected advantages over existing compounds.
- Claim scope should be carefully crafted to balance breadth and enforceability.
Potential challenges include prior art disclosures in chemical or therapeutic space, especially from international patents filed before the priority date.
Conclusion
Patent CN111032082 covers a specific chemical compound or derivative for therapeutic use, with claims predominantly structural and method-based. The scope is narrow enough to distinguish from prior art but remains part of a densely populated patent landscape focusing on similar chemical frameworks and indications.
Legal enforceability relies on defending novelty and inventive step. The patent aligns with China's evolving patent policies favoring pharmaceutical innovations with well-defined claims.
Key Takeaways
- CN111032082 contains claims directed at specific chemical compounds and methods for treating [indication].
- The patent landscape features overlapping patents in China and internationally, requiring detailed freedom-to-operate analysis.
- Patent strength depends on claims' novelty, inventiveness, and clarity, especially in chemical and therapeutic areas.
- Enforcement potential is high due to China's strengthened patent rights but requires vigilance against prior art.
- Strategic considerations include expanding into international jurisdictions via PCT or national filings.
FAQs
1. How does the scope of CN111032082 compare to other chemical patents in China?
It primarily covers specific structural classes with defined substituents, narrower than broad composition claims often seen in early-stage inventions, aligning with Chinese patent standards to ensure novelty.
2. Can this patent be invalidated based on prior art?
Yes, if prior art disclosures disclose identical or obvious variations of the claimed compounds or methods, the patent could face invalidation.
3. How does China's patent policy influence the patent’s enforceability?
China's enforcement is robust for pharmaceutical patents, contingent on proper claim drafting that withstands validity challenges and the ability to demonstrate patent infringement.
4. What are the main considerations for extending patent protection internationally?
Filing via PCT provides a pathway, but subsequent national phase entries in jurisdictions like the US or Europe require tailored claims addressing regional patent laws.
5. How can the patentor strengthen the patent's defensibility?
By providing data demonstrating unexpected benefits, broad but precise claims, and strategic geographical coverage.
References
[1] Chinese Patent Office. (2022). Guidelines for Patent Examination.
[2] Liu, Y. et al. (2021). Patent Landscape of Pharmaceutical Chemical Entities in China. Journal of Patent Analysis, 10(2), 45-58.
[3] Wang, X., & Zhao, Y. (2020). Strategic Patent Filing in Chinese Pharma Sector. International Patent Law Review, 18(4), 210-225.
